Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-03-14
2006-03-14
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C552S542000
Reexamination Certificate
active
07012069
ABSTRACT:
A compound of formula (I):Each of R1, R2, R3, R4, R4′, R5, R6, R7, R11, R12, R15, R16, and R17, independently, is hydrogen, halo, alkyl, haloalkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or alkyl that is optionally inserted with —NH—, —N(alkyl)—, —O—, —S—, —SO—, —SO2—, —O—SO2—, —SO2—O—, —SO3—O—, —CO—, —CO—O—, —O—CO—, —CO—NR′—, or —NR′—CO—; or R3and R4together, R4and R5together, R5and R6together, or R6and R7together are eliminated so that a C═C bond is formed between the carbons to which they are attached; each of R8, R9, R10, R13, and R14, independently, is hydrogen, halo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; n is 0, 1, or 2; A is alkylene, alkenylene, or alkynylene; and each of X, Y, and Z, independently, is alkyl, haloalkyl, —OR′, —SR′, —NR′R″, —N(OR′)R″, or —N(SR′)R″; or X and Y together are ═O, ═S, or ═NR′; wherein each of R′ and R″, independently, is hydrogen, alkyl, or haloalkyl.
REFERENCES:
patent: 5332851 (1994-07-01), Kumai et al.
patent: 110729 (1995-03-01), None
patent: 123286388 (1995-03-01), None
Charles Freudenreich, et al., “Design of Inhibitors from the Three-Dimensional Structure of Alcohol Dehydrogenase, Chemical Synthesis and Enzymatic Properties”,J. Am. Chem. Soc., pp. 3344-3353, (1984).
Bethany A. Janowski, et al., “Structural requirements of ligands for the oxysterol liver X receptors LXRa and LXRb”,Proc. Natl. Acad. Sci., USA, vol. 96, pp. 266-271, (Jan. 1999).
Bryan A. Laffitte, et al., “LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes”,PNAS, vol. 98, pp. 507-512, (Jun. 16, 2001).
Yvonne Lange, et al., “Cholesterol Movement in Niemann-Pick Type C Cells and in Cells Treated with Amphiphiles”,The Journal of Biological Chemistry, vol. 275, No. 23, pp. 17468-17475, (Jun. 9, 2000).
Cohen-Solal et al., “Effects of hyodeoxycholic acid and alpha-hyocholic acid, two 6 alpha-hydroxylated bile acids, on cholesterol and bile acid metabolism in the hamster”,Biochimica et biophysica Acta, 1257:189-197 (1995).
English language translation of Kuritzkes et al., “3-epi-Uzarigenin and 3-epa-17α-Uzarigenin”,Helvetica Chimica Acta, 14:1502-1515 (1959).
English language translation of Polonia et al., “Die Konstitution des Xysmalogenins”,Helvetica Chimica Acta, 11:1437-1446 (1959).
English language translation of Tamm et al., “Umwandlung von Cardenoliden durch Mikroorganismen. III. Umsetzung von Aglykonen und Glykosiden mit Fusarium lini”,Helvetica Chimica Acta, 21: 239-259 (1959).
English language translation of Tschesche et al., “Uber pflanzliche Herzgifte, XIX. Mitteil., Die Glykoside der Uzara-Wurzel”,Chemische Berichte, 85thvol., No. 11:1042-1053 (1952).
McKee et al., “HIV-Inhibitory Natural Products. 11. Comparitive Studies of Sulfated Sterols from Marine Invertebrates”,J. Med. Chem., 37:793-797 (1994).
Riccio et al., “Unusual Sulfated Marine Steroids from the OphiuroidOphioderma Longicaudum”,Tetrahedron, 41(24):6041-6046 (1985).
Liao Shutsung
Song Ching
ARCH Development Corporation
Badio Barbara P.
Fish & Richardson P.C.
LandOfFree
Liver X receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liver X receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liver X receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594408